(Q42968499)

11 November 2017

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma (English)

1 reference

11 November 2017

Ming-Mo Hou

1

1 reference

11 November 2017

Jia-Juan Hsieh

2

1 reference

11 November 2017

Nai-Jen Chang

3

1 reference

11 November 2017

Hsuan-Ying Huang

4

1 reference

11 November 2017

Hung-Ming Wang

5

1 reference

11 November 2017

Cheng-Keng Chuang

6

1 reference

11 November 2017

Todd Hsu

7

1 reference

11 November 2017

John Wen-Cheng Chang

8

1 reference

11 November 2017

1 January 2010

1 reference

Clinical Drug Investigation

11 November 2017

1 reference

11 November 2017

30

1 reference

11 November 2017

11

1 reference

11 November 2017

799-804

1 reference

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents

11 November 2017

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11537220-000000000-00000

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

12 December 2020

Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study

1 reference

12 December 2020

Translocation carcinomas of the kidney

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults

1 reference

12 December 2020

The bHLH-Zip transcription factor Tfeb is essential for placental vascularization

1 reference

12 December 2020

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).

1 reference

12 December 2020

PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

1 reference

12 December 2020

Morphologic and molecular characterization of renal cell carcinoma in children and young adults

1 reference

12 December 2020

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma

1 reference

12 December 2020

Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.

1 reference

12 December 2020

Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas

1 reference

12 December 2020

An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib

1 reference

12 December 2020

10.2165/11537220-000000000-00000

Identifiers

DOI

1 reference

11 November 2017

1 reference